GlaxoSmithKline Drops On Cancer Vaccine Trial Failure

Trial results showed a promising GlaxoSmithKline vaccine failed to help skin cancer patients, the company said Thursday. Shares of GlaxoSmithKline (GSK) fell 53 cents to $51.43. Glaxo said the vaccine, called MAGE-A3, didn’t increase the length of time melanoma patients lived without the disease returning. The 1,345 trial patients received the vaccine or placebo after tumors were [...]